BioSpace News Archive

Moog Inc. (NYSE: MOG.A and MOG.B) announced today that a notice of redemption is being issued to the holders of the Company’s 5.25% senior notes due in 2022 (the “Notes”), to redeem and retire all of the outstanding Notes.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic fibrosis (CF) reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency,

The U.S. Food and Drug Administration today cleared for marketing in the U.S. the first fully disposable duodenoscope.

ITF Pharma, a U.S.-based specialty pharmaceutical company and subsidiary of Italfarmaco, a privately-held European specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved its application to broaden the existing label for TIGLUTIK®

Takeda Pharmaceuticals U.S.A. (TSE: 4502) (NYSE:TAK) (“Takeda”) and MiTest Health LLC (“MiTest”), a pioneering health technology company, today announced an exclusive partnership to optimize MiTest’s personalized risk and outcome prediction tool for widespread use in patients with Crohn’s disease (CD).

Susan G. Komen®, the world’s leading breast cancer organization, today commended the results of a clinical trial, led by Komen Scholar Dr. Bryan Schneider, that moves us closer to predicting recurrence and informing the treatment of triple negative breast cancer (TNBC)

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the closing of its previously announced underwritten public offering of 3,820,000 shares of its common stock at a public offering price of $22.25 per share.

PTC Therapeutics, Inc. announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of 59,150 shares of its common stock to 17 new employees.

West Pharmaceutical Services, Inc. announced that the Company’s Board of Directors has approved a first-quarter 2020 dividend of $0.16 per share.

Puration, Inc. (USOTC: PURA) today confirmed a scheduled update with more details on the company’s recently announced 2020 expansion plan to be released next week on Tuesday, December 17, 2019. PURA’s expansion is intended to substantially increase PURA’s 2020 prospects beyond its current $8 million revenue target.